Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
CRANBURY, N.J., March 23 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it received $2.5 million from AstraZeneca AB pursuant to the September 2009 amendment of the exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors for treatment of obesity and related indications. Payment of …
Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca Read More »